Cancer Genetics, Inc. provided preliminarily earnings guidance for the second quarter and six months ended June 30, 2013. In addition, management preliminarily estimates that for the three months ended June 30, 2013 operating loss was between $1.6 million and $1.9 million, compared to an operating loss of $2.2 million for the three months ended June 30, 2012. Management preliminarily estimates that for the three months ended June 30, 2013 gross profit was between $520,000 and $580,000, compared to a gross profit of $63,000 for the three months ended June 30, 2012.

Management preliminarily estimates that for the six months ended June 30, 2013 total revenue was between $3.0 million and $3.1 million, including no grant revenue, compared to total revenue for the six months ended June 30, 2012 of $2.0 million, which included $195,000 in grant revenue. Management estimates that for the six months ended June 30, 2013 operating loss was between $4.0 million and $4.3 million, compared to an operating loss of $4.0 million for the six months ended June 30, 2012. Management estimates that for the six months ended June 30, 2013 gross profit was between $670,000 and $730,000, compared to a gross profit of $75,000 for the six months ended June 30, 2012.